Accepted for/Published in: JMIR mHealth and uHealth
Date Submitted: Oct 11, 2021
Date Accepted: Feb 16, 2022
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Analysis of Publicly Available German Mobile Apps for Psoriasis Patients using the Mobile Application Rating Scale (MARS).
ABSTRACT
Background:
Psoriasis is a chronic inflammatory skin disease. The visibility of the erythematous plaques on the skin as well as the pain and itch caused by the skin lesions frequently leads to psychological distress in patients. Smartphone apps are widespread, easily accessible and could effectively complement current management strategies of psoriasis patients.
Objective:
To systematically identify and objectively assess the quality of currently publicly available German apps for psoriasis patients and compile brief, ready-to-use app descriptions.
Methods:
We conducted a systematic search and assessment of German apps for psoriasis patients available in the Google Play and Apple App Store. The identified apps were randomly assigned to and independently rated using the Mobile Application Rating Scale (MARS) by three reviewers. Apps were ranked accordingly to their mean MARS rating and the highest ranked app was evaluated independently by two psoriasis patients using the User Version of the Mobile Application Rating Scale (uMARS). App information, including origin, main function and technical aspects and was congregated.
Results:
In total, we were able to identify 95 different apps for psoriasis, of which 15 were available in both app stores, 5 were not specifically intended for psoriasis patients and 1 was designed for clinical trials only. Consequently, the remaining nine apps were included in the final evaluation. Mean MARS score varied between 3.51 and 4.18. The app with the highest mean MARS score was “Psoriasis Helferin” (4.18/5) . When rated by patients, the app was rated lower in all MARS subcategories, resulting in a mean uMARS score of 3.48.
Conclusions:
App quality was heterogenous and only a minority of identified apps was available in both app stores. The discrepant patient results highlight the importance of involving patients when developing and evaluating health apps. Clinical Trial: Deutsches Register klinische Studien (DRKS): DRKS00020963
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.